Form 8-K - Current report:
SEC Accession No. 0001193125-25-105845
Filing Date
2025-04-30
Accepted
2025-04-30 08:27:03
Documents
17
Period of Report
2025-04-29
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d873263d8k.htm   iXBRL 8-K 69669
2 EX-2.1 d873263dex21.htm EX-2.1 659594
3 EX-99.1 d873263dex991.htm EX-99.1 15297
7 GRAPHIC g873263g0430101118423.jpg GRAPHIC 3298
8 GRAPHIC g873263g0430101118582.jpg GRAPHIC 3420
  Complete submission text file 0001193125-25-105845.txt   1059278

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA rgls-20250429.xsd EX-101.SCH 2856
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE rgls-20250429_lab.xml EX-101.LAB 17994
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rgls-20250429_pre.xml EX-101.PRE 11265
19 EXTRACTED XBRL INSTANCE DOCUMENT d873263d8k_htm.xml XML 3645
Mailing Address 4224 CAMPUS POINT COURT SUITE 210 SAN DIEGO CA 92121
Business Address 4224 CAMPUS POINT COURT SUITE 210 SAN DIEGO CA 92121 858-202-6300
Regulus Therapeutics Inc. (Filer) CIK: 0001505512 (see all company filings)

EIN.: 264738379 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35670 | Film No.: 25891153
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)